AstraZeneca Tops Earnings Views And Shares Rise Despite Cancer Miss
In This Article:
AstraZeneca stock rose moderately Tuesday despite a mixed first-quarter report and a setback for its experimental prostate cancer treatment.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
AstraZeneca stock rose moderately Tuesday despite a mixed first-quarter report and a setback for its experimental prostate cancer treatment.